aTyr Pharma announces EAP for EFZO-FIT clinical trial participants

aTyr Pharma announced plans to initiate an Individual Patient Expanded Access Program, EAP, for its lead therapeutic candidate, efzofitimod, for patients with pulmonary sarcoidosis. The Individual Patient EAP is intended to allow access for patients who complete the Phase 3 EFZO-FIT study and wish to receive treatment with efzofitimod outside of the clinical trial. “We are pleased to make efzofitimod available to patients beyond the duration of the EFZO-FIT clinical trial through this Individual Patient EAP,” said Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer of aTyr. “Based on interest from Principal Investigators and patients who have or are in the process of completing the EFZO-FIT study, we have decided to implement this program in part to continue to support those patients who have dedicated their time and entrusted us with their health by participating in this important study. This program reflects our ongoing commitment to the sarcoidosis community as we work to develop a safe and effective treatment for a condition that has a high unmet medical need.”